This “rare” autism

Billy Odell Tucker-Robinson Founder & Host — Banking With Billy Network • Intelligence Network • Data Science • AI Research • World News
Published: 2026-09-25T14:00:21.550Z • Permanent link

A major analysis published by researchers at the University of California, San Francisco, has shed new light on Phelan-McDermid syndrome, a genetic disorder closely linked to autism. Led by Dr. Susan Nelson, the study estimates that the syndrome affects approximately 1 in 7,300 people worldwide, with over 45,000 Americans living with the condition. Dr. Nelson's team used advanced genetic testing to identify the syndrome, which is caused by a deletion of genetic material on chromosome 22. The researchers warn that thousands of cases may remain hidden due to the limitations of genetic testing, highlighting the need for further research and improved diagnostic tools.

The analysis was conducted in collaboration with the National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC). The study's findings are based on data from the NIH's Genetic and Rare Diseases Information Center (GARD) and the CDC's Autism and Developmental Disabilities Monitoring Network (ADDM). The researchers also drew on data from the University of California, Los Angeles (UCLA), where Dr. Nelson is a professor of pediatrics. The study's results are expected to have significant implications for the diagnosis and treatment of Phelan-McDermid syndrome, as well as for the broader field of autism research.

The study's lead author, Dr. Nelson, is a renowned expert in the field of autism and genetic disorders. Dr. Nelson has published numerous papers on the topic and has served as a consultant to several pharmaceutical companies, including Biogen and Pfizer. Her work has focused on the development of diagnostic tests and treatments for individuals with Phelan-McDermid syndrome and other genetic disorders.

Phelan-McDermid syndrome has significant implications for the biotech and medical industries, where companies are racing to develop new treatments and diagnostic tools for individuals with the condition. Companies such as Biogen and Pfizer are already working on new therapies for Phelan-McDermid syndrome, including gene therapies and small molecule treatments. The development of these treatments is expected to be costly, with estimates suggesting that a single gene therapy treatment could cost upwards of $1 million per patient. As a result, the study's findings are likely to have a significant impact on the pricing and availability of these treatments.

The study's results also have implications for research communities and policy environments. Researchers are likely to be eager to learn more about the genetic basis of Phelan-McDermid syndrome, in order to develop more effective diagnostic tests and treatments. Policy makers may also take notice of the study's findings, as they seek to improve access to healthcare for individuals with rare genetic disorders. The study's lead author, Dr. Nelson, has already called for greater investment in research and diagnostic tools for individuals with Phelan-McDermid syndrome, stating that "we need to do more to improve our understanding of this condition and to develop more effective treatments.

Phelan-McDermid syndrome is not an isolated condition, but rather one of several genetic disorders that are closely linked to autism. Research has shown that individuals with Phelan-McDermid syndrome are at increased risk of developing other conditions, including epilepsy, intellectual disability, and behavioral problems. The study's findings are part of a larger trend in autism research, which has highlighted the importance of genetic testing and diagnostic tools in identifying individuals with the condition.